The protein product of the GALNT14 gene may serve oncogenic roles and regulate anti-cancer drug sensitivity in multiple cancers, including hepatocellular carcinoma [50], possibly through modulating downstream effector glycosylation. The gene discussed is GALNT14; the disease is cancer.